ArticleMetabolic brain disease2026
A multi-target approach using Moringa oleifera leaf extract in ameliorating PTZ-induced epilepsy-like neurobehavior in male rats: in vivo and in silico study.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although a variety of antiepileptic medications are available, their administration often leads to undesirable side effects. In the present study, we investigated the effect of Moringa oleifera leaf extract (MOLE) against neurodegenerative pathophysiology relevant to PTZ-induced epilepsy-like neurobehavior in the hippocampus of rats. Forty male rats were allocated into four groups: control group, MOLE group, PTZ group, and PTZ plus MOLE group. MOLE (300 mg/kg) was administered orally for 35 days, while PTZ (40 mg/kg) was injected intraperitoneally in nine doses on alternate days, commencing on the 18th day. Phytochemical analysis using GC-MS and molecular docking was performed. Animals were behaviorally assessed using open field and elevated plus maze tests. The hippocampal tissue was evaluated for malondialdehyde, nitric oxide, reduced glutathione, glutathione peroxidase, superoxide dismutase, catalase, tumor necrosis factor-α, interleukin-1β and 6, acetylcholine, acetylcholinesterase, gamma-aminobutyric acid, glutamate, and monoamine oxidase. NF-kB expression, histopathological alterations, caspase-3, and GFAP immunoreactivity were investigated. The GC-MS analysis revealed the presence of various phytochemicals. MOLE attenuated PTZ-induced behavioral changes and improved the oxidant/antioxidant status of the hippocampus. MOLE also reduced the pro-inflammatory cytokines, modulated the neurochemicals, and regulated the expression of NF-κB. Furthermore, MOLE improved the histopathological and the immunohistochemical deteriorations in the hippocampus. Molecular docking analysis showed robust binding affinities for the major phytochemicals to proteins involved in neuroinflammation, oxidative stress, and regulation of neurotransmission. These findings highlight the efficacy of MOLE as a potential multi-target approach against PTZ-induced epilepsy-like neurobehavior, attributed to its diverse bioactive phytochemicals with antioxidative, anti-inflammatory, neuromodulator, and NF-κB regulatory properties.
Indexed as
Identifiers
42455182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.